Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Charles River Laboratories

Charles River Laboratories Earnings Preview: What to Expect

Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit drop in the company’s bottom-line figure.

How Is Charles River Laboratories’ Stock Performance Compared to Other Health Care Stocks?

How Is Charles River Laboratories’ Stock Performance Compared to Other Health Care Stocks?

Despite underperforming its industry peers over the past year, analysts remain highly bullish on Charles River Laboratories' long-term prospects.

What to Expect From Charles River Laboratories’ Next Quarterly Earnings Report

What to Expect From Charles River Laboratories’ Next Quarterly Earnings Report

Charles River Laboratories is scheduled to report its fiscal fourth-quarter results shortly, with analysts forecasting a low–double-digit year-over-year decline in earnings.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Is Charles River Laboratories Stock Underperforming the Dow?

Despite lagging the Dow Jones Industrial Average over the past year, Charles River Laboratories continues to attract cautious optimism from analysts regarding its longer-term outlook.

Charles River Laboratories Stock: Is Wall Street Bullish or Bearish?

Charles River Laboratories has continued to underperform the broader market over the past year, yet analysts remain moderately bullish on the stock’s prospects.

Is Charles River Laboratories Stock Underperforming the Nasdaq?

Charles River Laboratories has significantly underperformed the Nasdaq Composite over the past year, yet analysts remain cautiously optimistic about the stock’s prospects.

Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing

Charles River Laboratories International Inc. (NYSE:CRL) stock is trading lower on Wednesday after the company released second-quarter 2025 earnings.

inkl

Read news from The Economist, FT, and more,
with one subscription

Here's What to Expect From Charles River Laboratories' Next Earnings Report

Here's What to Expect From Charles River Laboratories' Next Earnings Report

Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit drop in the company’s bottom-line figure.

Is Charles River Laboratories Stock Underperforming the S&P 500?

Is Charles River Laboratories Stock Underperforming the S&P 500?

Despite Charles River Laboratories' weak performance relative to the broader S&P 500 Index over the past year, Wall Street analysts remain moderately optimistic about its prospects.

Earnings Preview: What To Expect From Charles River Laboratories' Report

Earnings Preview: What To Expect From Charles River Laboratories' Report

Charles River Laboratories is scheduled to announce its first-quarter results next week, with analysts anticipating a single-digit earnings dip.

The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?

The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?

Amid market turbulence and policy shifts, do two of the S&P 500’s steepest decliners, DECK and CRL, offer deep value or signal deeper trouble ahead?

Charles River Laboratories Stock Outlook: Is Wall Street Bullish or Bearish?

Charles River Laboratories Stock Outlook: Is Wall Street Bullish or Bearish?

Charles River Laboratories has lagged behind the broader market over the past year, with Wall Street analysts maintaining a cautious outlook on its future performance.

Charles River Laboratories' Q3 2024 Earnings: What to Expect

Charles River Laboratories' Q3 2024 Earnings: What to Expect

Charles River Laboratories is expected to announce its third-quarter results next month, and analysts predict a double-digit decline in the company’s bottom-line figure.

Is Charles River Laboratories Stock Underperforming the Dow?

Is Charles River Laboratories Stock Underperforming the Dow?

Charles River Laboratories underperformed the Dow recently, but Wall Street analysts remain moderately optimistic about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Charles River Laboratories Earnings Preview: What to Expect

Charles River Laboratories is poised to release its second-quarter earnings next month, and analysts expect a double-digit earnings dip.

Stocks Settle Mixed as 10-Year T-note Yield Stays Above 4%

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.17%. Stocks on Tuesday settled mixed. Reduced expectations for...

Coastal biomedical labs are bleeding more horseshoe crabs with little accountability

Horseshoe crab blood is used to test vaccines around the world. But while Europe has approved a synthetic alternative, biomedical labs are bleeding more crabs from the Atlantic Coast.

Does Charles River Laboratories International Deserve a Place in Your Portfolio?

The shares of Charles River Laboratories (CRL) have plunged in price despite the company’s solid results. So, can they rebound by the company leveraging its broad portfolio of products and services? Read on. Let’s find out.

Get all your
news in one place.

100's of premium titles.
One news app.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the Wall Street Journal

Verizon Communications

Juniper Networks

United Airlines Holdings

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

398,244 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play